—TRIADE Designed to Address Excessive Placebo Response, a Prime Cause of Depression Trial Failure— —Trial Further Evaluates Amitifadine, Euthymics’ Proprietary Serotonin-Preferring Triple— CAMBRIDGE, ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive ...
Euthymics Bioscience, Inc. announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of Major Depressive Disorder (MDD). The TRIADE (Triple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results